Breast
- (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
- (131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)
-
(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics
and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors
and C-Met Dysregulation
-
(167-18) A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
-
(173-18) Perioperative Mindfulness Proposal
-
(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity
of ASTX029 in Subjects With Advanced Solid Tumors
-
(182-20) 18F-FLUORESTRADIOL (FES) PET/CT COMPARED TO STANDARD-OF-CARE IMAGING
IN PATIENTS WITH BREAST CANCER (Phase 2 clinical trial, appropriate for
patients with breast cancer.)
-
(187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
-
(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal
Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1
Monoclonal Antibody, in Subjects with Advanced Cancer
-
(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors
-
(189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With
Metastatic Solid Tumors
-
(205-19) Study to Assess AFM24 in Advanced Solid Cancers
-
(214-17) An Investigational Immunotherapy Study of BMS-986258 Alone and
in Combination With Nivolumab in Participants With Solid Cancers That
Are Advanced or Have Spread
-
(221-19) Study of GNX102 in Patients With Advanced Solid Tumors
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.